|
1
|
Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W,
Dong XY, Peng JR, Zhao HT, Rui JA, Leng XS, et al: Large scale
identification of human hepatocellular carcinoma-associated
antigens by autoantibodies. J Immunol. 169:1102–1109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lucas S, De Plaen E and Boon T: MAGE-B5,
MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family
with tumor-specific expression. Int J Cancer. 87:55–60. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zendman AJ, Ruiter DJ and Van Muijen GN:
Cancer/testis-associated genes: Identification, expression profile,
and putative function. J Cell Physiol. 194:272–288. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chomez P, De Backer O, Bertrand M, De
Plaen E, Boon T and Lucas S: An overview of the MAGE gene family
with the identification of all human members of the family. Cancer
Res. 61:5544–5551. 2001.PubMed/NCBI
|
|
5
|
Barker PA and Salehi A: The MAGE proteins:
Emerging roles in cell cycle progression, apoptosis, and
neurogenetic disease. J Neurosci Res. 67:705–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goodyear O, Agathanggelou A,
Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh
J, Stankovic T, Moss P and Craddock C: Induction of a CD8+ T-cell
response to the MAGE cancer testis antigen by combined treatment
with azacitidine and sodium valproate in patients with acute
myeloid leukemia and myelodysplasia. Blood. 116:1908–1918. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Francois V, Ottaviani S, Renkvist N,
Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T,
Lucas S and van der Bruggen P: The CD4(+) T-cell response of
melanoma patients to a MAGE-A3 peptide vaccine involves potential
regulatory T cells. Cancer Res. 69:4335–4345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oehlrich N, Devitt G, Linnebacher M,
Schwitalle Y, Grosskinski S, Stevanovic S and Zöller M: Generation
of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines
for transfer in patients with renal cell carcinoma. Int J Cancer.
117:256–264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tatsumi T, Kierstead LS, Ranieri E,
Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J,
Sette A, et al: MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes
recognized by CD4+ T cells from patients with melanoma or renal
cell carcinoma. Clin Cancer Res. 9:947–954. 2003.PubMed/NCBI
|
|
10
|
Vansteenkiste J, Zielinski M, Linder A,
Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T,
Jassem J, Kalofonos H, et al: Adjuvant MAGE-A3 immunotherapy in
resected non-small-cell lung cancer: Phase II randomized study
results. J Clin Oncol. 31:2396–2403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vantomme V, Dantinne C, Amrani N, Permanne
P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH,
et al: Immunologic analysis of a phase I/II study of vaccination
with MAGE-3 protein combined with the AS02B adjuvant in patients
with MAGE-3-positive tumors. J Immunother. 27:124–135. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Baren N, Bonnet MC, Dréno B, Khammari
A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M,
Brichard VG, et al: Tumoral and immunologic response after
vaccination of melanoma patients with an ALVAC virus encoding MAGE
antigens recognized by T cells. J Clin Oncol. 23:9008–9021. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aleksić MM, Kapetanović V, Atanacković J,
Jocić B and Zecević M: Simultaneous determination of cefotaxime and
desacetylcefotaxime in real urine sample using voltammetric and
high-performance liquid chromatographic methods. Talanta.
77:131–137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
No authors listed: CD4 T-cell
immunotherapy shows early promise. Cancer Discov. 6:567–568. 2016.
View Article : Google Scholar
|
|
15
|
Hao J, Song X, Wang J, Guo C, Li Y, Li B,
Zhang Y and Yin Y: Cancer-testis antigen MAGE-C2 binds Rbx1 and
inhibits ubiquitin ligase-mediated turnover of cyclin E.
Oncotarget. 6:42028–42039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang B, O'Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ayyoub M, Scarlata CM, Hamai A, Pignon P
and Valmori D: Expression of MAGE-A3/6 in primary breast cancer is
associated with hormone receptor negative status, high histologic
grade, and poor survival. J Immunother. 37:73–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang F, Zhou X, Miao X, Zhang T, Hang X,
Tie R, Liu N, Tian F, Wang F and Yuan J: MAGEC2, an
epithelial-mesenchymal transition inducer, is associated with
breast cancer metastasis. Breast Cancer Res Treat. 145:23–32. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weon JL and Potts PR: The MAGE protein
family and cancer. Curr Opin Cell Biol. 37:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
von Boehmer L, Keller L, Mortezavi A,
Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ,
Kristiansen G, et al: MAGE-C2/CT10 protein expression is an
independent predictor of recurrence in prostate cancer. PLoS One.
6:e213662011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song X, Hao J, Wang J, Guo C, Wang Y, He
Q, Tang H, Qin X, Li Y, Zhang Y and Yin Y: The cancer/testis
antigen MAGEC2 promotes amoeboid invasion of tumor cells by
enhancing STAT3 signaling. Oncogene. 36:1476–1486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uesugi M, Nyanguile O, Lu H, Levine AJ and
Verdine GL: Induced alpha helix in the VP16 activation domain upon
binding to a human TAF. Science. 277:1310–1313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Piskacek S, Gregor M, Nemethova M, Grabner
M, Kovarik P and Piskacek M: Nine-amino-acid transactivation
domain: Establishment and prediction utilities. Genomics.
89:756–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B, Qian XP, Pang XW, Zou WZ, Wang YP,
Wu HY and Chen WF: HCA587 antigen expression in normal tissues and
cancers: Correlation with tumor differentiation in hepatocellular
carcinoma. Lab Invest. 83:1185–1192. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y,
Chen LH, Ouyang WM, Xu XG, Jian JL, Güre AO, et al: Generation of
monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2.
Cancer Immun. 6:72006.PubMed/NCBI
|
|
27
|
Chen J, Zhang L, Wen W, Hao J, Zeng P,
Qian X, Zhang Y and Yin Y: Induction of HCA587-specific antitumor
immunity with HCA587 protein formulated with CpG and ISCOM in mice.
PLoS One. 7:e472192012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma W, Germeau C, Vigneron N, Maernoudt AS,
Morel S, Boon T, Coulie PG and Van den Eynde BJ: Two new
tumor-specific antigenic peptides encoded by gene MAGE-C2 and
presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer.
109:698–702. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li B, He X, Pang X, Zhang H, Chen J and
Chen W: Elicitation of both CD4 and CD8 T-cell-mediated specific
immune responses to HCA587 protein by autologous dendritic cells.
Scand J Immunol. 60:506–513. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma W, Vigneron N, Chapiro J, Stroobant V,
Germeau C, Boon T, Coulie PG and Van den Eynde BJ: A MAGE-C2
antigenic peptide processed by the immunoproteasome is recognized
by cytolytic T cells isolated from a melanoma patient after
successful immunotherapy. Int J Cancer. 129:2427–2434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xing Q, Pang XW, Peng JR, Yin YH, Li Y, Yu
X, Zhou SP, Zhang Y and Chen WF: Identification of new cytotoxic
T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem
Biophys Res Commun. 372:331–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wen W, Zhang L, Peng J, Chen J, Hao J, Li
X, Qian X, Zeng P, Zhang Y and Yin Y: Identification of promiscuous
HLA-DR-restricted CD4+ T-cell epitopes on the cancer-testis antigen
HCA587. Cancer Sci. 102:1455–1461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Carvalho F, Costa ET, Camargo AA,
Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL,
Atanackovic D and Colleoni GW: Targeting MAGE-C1/CT7 expression
increases cell sensitivity to the proteasome inhibitor bortezomib
in multiple myeloma cell lines. PLoS One. 6:e277072011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Curioni-Fontecedro A, Nuber N,
Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den
Broek M and Moch H: Expression of MAGE-C1/CT7 and MAGE-C2/CT10
predicts lymph node metastasis in melanoma patients. PLoS One.
6:e214182011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grant PA, Schieltz D, Pray-Grant MG,
Steger DJ, Reese JC, Yates JR III and Workman JL: A subset of
TAF(II)s are integral components of the SAGA complex required for
nucleosome acetylation and transcriptional stimulation. Cell.
94:45–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Milgrom E, West RW Jr, Gao C and Shen WC:
TFIID and Spt-Ada-Gcn5-acetyltransferase functions probed by
genome-wide synthetic genetic array analysis using a Saccharomyces
cerevisiae taf9-ts allele. Genetics. 171:959–973. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen WC, Bhaumik SR, Causton HC, Simon I,
Zhu X, Jennings EG, Wang TH, Young RA and Green MR: Systematic
analysis of essential yeast TAFs in genome-wide transcription and
preinitiation complex assembly. EMBO J. 22:3395–3402. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moqtaderi Z, Keaveney M and Struhl K: The
histone H3-like TAF is broadly required for transcription in yeast.
Mol Cell. 2:675–682. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu PY, Ruhlmann C, Winston F and Schultz
P: Molecular architecture of the S. Cerevisiae SAGA complex. Mol
Cell. 15:199–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Timmers HT and Tora L: SAGA unveiled.
Trends Biochem Sci. 30:7–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nault JC, De Reyniès A, Villanueva A,
Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud
S, Rousseau F, et al: A hepatocellular carcinoma 5-gene score
associated with survival of patients after liver resection.
Gastroenterology. 145:176–187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bosco-Clément G, Zhang F, Chen Z, Zhou HM,
Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, et al:
Targeting Gli transcription activation by small molecule suppresses
tumor growth. Oncogene. 33:2087–2097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shao H, Revach M, Moshonov S, Tzuman Y,
Gazit K, Albeck S, Unger T and Dikstein R: Core promoter binding by
histone-like TAF complexes. Mol Cell Biol. 25:206–219. 2005.
View Article : Google Scholar : PubMed/NCBI
|
